Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
BACKGROUND This article addresses the treatment of VTE disease. METHODS We generated strong (Grade 1) and weak (Grade 2) recommendations based on high-quality (Grade A), moderate-quality (Grade B),… Expand
The Long-Term Clinical Course of Acute Deep Venous Thrombosis
Deep venous thrombosis of the lower extremity is a serious disorder; the estimated incidence is 1 per 1000 persons per year [1-3]. The disease can occur after surgical procedures and trauma and in… Expand
Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism.
BACKGROUND Chronic thromboembolic pulmonary hypertension (CTPH) is associated with considerable morbidity and mortality. Its incidence after pulmonary embolism and associated risk factors are not… Expand
Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis.
A small proportion of patients with deep vein thrombosis develop recurrent venous thromboembolic complications or bleeding during anticoagulant treatment. These complications may occur more… Expand
A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Padua Prediction Score
- S. Barbar, F. Noventa, +7 authors P. Prandoni
- Journal of thrombosis and haemostasis : JTH
- 1 November 2010
Summary. Background: Prophylaxis of venous thromboembolism (VTE) in hospitalized medical patients is largely underused. We sought to assess the value of a simple risk assessment model (RAM) for the… Expand
Upper-extremity deep vein thrombosis. Risk factors, diagnosis, and complications.
- P. Prandoni, P. Polistena, +8 authors A. Girolami
- Archives of internal medicine
- 13 January 1997
BACKGROUND Little is known about the clinical, diagnostic, and prognostic aspects of upper-extremity deep vein thrombosis (UEDVT). OBJECTIVES To identify the clinical and laboratory parameters… Expand
Rivaroxaban: population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention.
- W. Mueck, A. Lensing, G. Agnelli, H. Décousus, P. Prandoni, F. Misselwitz
- Clinical pharmacokinetics
BACKGROUND AND OBJECTIVE Rivaroxaban is an oral, direct Factor Xa inhibitor, which is at an advanced stage of clinical development for prevention and treatment of thromboembolic disorders. Two phase… Expand
The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626…
BACKGROUND AND OBJECTIVES While it has long been recognized that patients with acute unprovoked deep vein thrombosis (DVT) or pulmonary embolism (PE) have a higher risk of recurrent venous… Expand
Below-knee elastic compression stockings to prevent the post-thrombotic syndrome: A randomized, controlled trial
The effect of low molecular weight heparin on survival in patients with advanced malignancy.
- C. Klerk, Susanne M. Smorenburg, +8 authors H. Büller
- Medicine, Biology
- Journal of clinical oncology : official journal…
- 1 April 2005
PURPOSE Studies in cancer patients with venous thromboembolism suggested that low molecular weight heparin may prolong survival. In a double-blind study, we evaluated the effect of low molecular… Expand